Q4 EPS Estimates for Zimmer Biomet Cut by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Research analysts at Zacks Research decreased their Q4 2025 earnings per share estimates for shares of Zimmer Biomet in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.37 per share for the quarter, down from their previous estimate of $2.38. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.65 earnings per share.

Other analysts have also recently issued reports about the company. Evercore ISI cut their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. TD Cowen reduced their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Finally, Canaccord Genuity Group decreased their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Trading Up 0.1 %

Zimmer Biomet stock opened at $112.10 on Thursday. The stock has a 50-day simple moving average of $107.29 and a 200 day simple moving average of $109.45. The stock has a market capitalization of $22.32 billion, a P/E ratio of 21.31, a PEG ratio of 2.06 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet has a 52 week low of $101.47 and a 52 week high of $133.90.

Institutional Trading of Zimmer Biomet

Several large investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB lifted its position in Zimmer Biomet by 7.7% during the third quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider’s stock worth $669,000 after purchasing an additional 442 shares during the period. Sanctuary Advisors LLC lifted its holdings in shares of Zimmer Biomet by 26.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,825 shares of the medical equipment provider’s stock worth $1,965,000 after acquiring an additional 3,776 shares during the period. Toronto Dominion Bank boosted its position in shares of Zimmer Biomet by 14.5% during the 3rd quarter. Toronto Dominion Bank now owns 68,747 shares of the medical equipment provider’s stock worth $7,421,000 after acquiring an additional 8,710 shares in the last quarter. Neo Ivy Capital Management bought a new position in Zimmer Biomet in the third quarter valued at approximately $150,000. Finally, Brown Financial Advisors raised its position in Zimmer Biomet by 16.6% during the third quarter. Brown Financial Advisors now owns 9,566 shares of the medical equipment provider’s stock valued at $1,033,000 after purchasing an additional 1,361 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.